<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wilcox JM</submitter><funding>NICHD NIH HHS</funding><funding>NIA NIH HHS</funding><funding>NIEHS NIH HHS</funding><funding>National Cancer Institute</funding><funding>NCI NIH HHS</funding><funding>National Institutes of Health</funding><funding>NIH HHS</funding><funding>Vanderbilt University Medical Center</funding><pagination>94-105</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8761387</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>87</volume><pubmed_abstract>Manganese (Mn) is an essential micronutrient but excessive levels induce neurotoxic effects. Increasing evidence suggests a deficit of bioavailable Mn in Huntington disease (HD), an inherited neurodegenerative disease characterized by motor and cognitive disturbances. Previous studies have shown rescue of some molecular HD phenotypes by acute Mn exposure. This study simultaneously examined the potential for chronic Mn exposure to attenuate HD behavioral phenotypes, and for the HD genotype to offer protection against detrimental effects of chronic Mn exposure. In two independent studies a chronic Mn exposure paradigm was implemented in the YAC128 mouse model of HD and behavior was assessed at several timepoints. Study 1 exposed WT and YAC128 mice to twice weekly subcutaneous injections of 0</pubmed_abstract><journal>Neurotoxicology</journal><pubmed_title>YAC128 mouse model of Huntington disease is protected against subtle chronic manganese (Mn)-induced behavioral and neuropathological changes.</pubmed_title><pmcid>PMC8761387</pmcid><funding_grant_id>S10 OD023475-01A1</funding_grant_id><funding_grant_id>R01 ES016931</funding_grant_id><funding_grant_id>S10 OD023475</funding_grant_id><funding_grant_id>T32 AG058524</funding_grant_id><funding_grant_id>P50 HD103537</funding_grant_id><funding_grant_id>P30 CA068485</funding_grant_id><funding_grant_id>5P30 CA68485-19</funding_grant_id><funding_grant_id>T32 ES007028</funding_grant_id><funding_grant_id>R01 ES031401</funding_grant_id><pubmed_authors>Wilcox JM</pubmed_authors><pubmed_authors>Pfalzer AC</pubmed_authors><pubmed_authors>Debbiche IF</pubmed_authors><pubmed_authors>Harrison FE</pubmed_authors><pubmed_authors>Cox EC</pubmed_authors><pubmed_authors>Bowman AB</pubmed_authors><pubmed_authors>Erikson KM</pubmed_authors><pubmed_authors>Tienda AA</pubmed_authors><pubmed_authors>Totten MS</pubmed_authors></additional><is_claimable>false</is_claimable><name>YAC128 mouse model of Huntington disease is protected against subtle chronic manganese (Mn)-induced behavioral and neuropathological changes.</name><description>Manganese (Mn) is an essential micronutrient but excessive levels induce neurotoxic effects. Increasing evidence suggests a deficit of bioavailable Mn in Huntington disease (HD), an inherited neurodegenerative disease characterized by motor and cognitive disturbances. Previous studies have shown rescue of some molecular HD phenotypes by acute Mn exposure. This study simultaneously examined the potential for chronic Mn exposure to attenuate HD behavioral phenotypes, and for the HD genotype to offer protection against detrimental effects of chronic Mn exposure. In two independent studies a chronic Mn exposure paradigm was implemented in the YAC128 mouse model of HD and behavior was assessed at several timepoints. Study 1 exposed WT and YAC128 mice to twice weekly subcutaneous injections of 0</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Dec</publication><modification>2025-04-05T09:43:57.658Z</modification><creation>2025-04-05T09:43:57.658Z</creation></dates><accession>S-EPMC8761387</accession><cross_references><pubmed>34543681</pubmed><doi>10.1016/j.neuro.2021.09.002</doi></cross_references></HashMap>